WRPWM
SRNE

Werba Rubin Papier Wealth Management’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Werba Rubin Papier Wealth Management’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-10,000
Closed -$3.6K – 130
2023
Q1 		$3.6K Buy
+10,000
New +$8.96K ﹤0.01% 115

Other funds holding SRNE

SW
SlateStone Wealth Jupiter, Florida $1.31B AUM 26.51% 1-Year Est. Return
KA
KLCM Advisors Milwaukee, Wisconsin $1.27B AUM 31.14% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return
AA
AlphaMark Advisors Ft. Wright, Kentucky $231M AUM 19.98% 1-Year Est. Return
OAJ
Ogorek Anthony Joseph Williamsville, New York $403M AUM 22.57% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
TCOV
Trust Company of Vermont Brattleboro, Vermont $2.68B AUM
CFGS
Concourse Financial Group Securities Birmingham, Alabama $1.77B AUM 17.37% 1-Year Est. Return

Werba Rubin Papier Wealth Management's SRNE Position: Q2 2023 in Review

Werba Rubin Papier Wealth Management sold out of Sorrento Therapeutics, Inc. (SRNE) in Q2 2023, closing a stake of 10,000 shares — an estimated $3.6K sold.

Werba Rubin Papier Wealth Management first reported a position in SRNE in Q1 2023 and held it in 1 quarter. The position peaked at $3.6K in Q1 2023. 9 funds tracked by Wall St. Rank hold SRNE as of Q2 2023.

  • Werba Rubin Papier Wealth Management reported no remaining Sorrento Therapeutics, Inc. position as of Q2 2023 after selling out during the quarter.
  • Werba Rubin Papier Wealth Management sold 10,000 Sorrento Therapeutics, Inc. shares in Q2 2023, an estimated $3.6K.
  • Werba Rubin Papier Wealth Management first reported a position in Sorrento Therapeutics, Inc. in Q1 2023 and held it in 1 quarter.
  • Werba Rubin Papier Wealth Management's Sorrento Therapeutics, Inc. position peaked at $3.6K in Q1 2023.
  • 9 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q2 2023.

Based on Werba Rubin Papier Wealth Management's 13F filing for Q2 2023, filed 24 Jul 2023.